Lead Product(s) : Velinotamig
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Cullinan Therapeutics
Deal Size : $712.0 million
Deal Type : Licensing Agreement
Cullinan's $700M Pact for BCMA Bispecific to Pair with Other TCE
Details : Under the licensing agreement, Cullinan will holds the exclusive rights to develop and commercialize GR-1803 (velinotamig) in all disease areas globally outside of Greater China.
Product Name : GR-1803
Product Type : Antibody
Upfront Cash : $20.0 million
June 05, 2025
Lead Product(s) : Velinotamig
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Cullinan Therapeutics
Deal Size : $712.0 million
Deal Type : Licensing Agreement
Lead Product(s) : NTB003
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Chia Tai Tianqing Pharmaceutical Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for NTB003
Details : NTB003 is a second-generation fully human anti-IGF-1R monoclonal antibody, being investigated for thyroid eye disease.
Product Name : BCG009
Product Type : Antibody
Upfront Cash : Inapplicable
June 04, 2025
Lead Product(s) : NTB003
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Chia Tai Tianqing Pharmaceutical Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : UC101
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : VectorBuilder
Deal Size : Inapplicable
Deal Type : Inapplicable
VectorBuilder Enables FDA IND for Cord Blood CAR-T Therapy
Details : UC101 is the world’s first FDA IND-approved umbilical cord blood-derived allogeneic CAR-T therapy. It is being evaluated to alleviate the risk of host-versus-graft response.
Product Name : UC101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 29, 2025
Lead Product(s) : UC101
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : VectorBuilder
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Equecabtagene Autoleucel
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves IASO Bio’s IND for Equecabtagene Autoleucel
Details : Fucaso (equecabtagene autoleucel) is a BCMA chimeric antigen receptor autologous T cell therapy, being investigated for the treatment of Non-renal Systemic Lupus Erythematosus.
Product Name : CT103A
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 08, 2024
Lead Product(s) : Equecabtagene Autoleucel
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LP-003
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LongBio's LP-003 Achieves Its Fourth IND Approval
Details : LP-003 is the company's next-generation anti-IgE antibody. Currently, it is being evaluated in the early-stage clinical trial studies for the treatment of food allergy.
Product Name : LP-003
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 25, 2024
Lead Product(s) : LP-003
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IASO-782
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IASO Bio Receives NMPA IND Approval for IASO-782 in Systemic Lupus Erythematosus
Details : IASO-782 Injection is a fully human monoclonal antibody targeting human CD19, with Fc mutations to enhance ADCC function for treatment of Systemic Lupus Erythematosus.
Product Name : IASO-782
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 25, 2024
Lead Product(s) : IASO-782
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Equecabtagene Autoleucel
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IASO Bio Announces FDA Approval for BCMA CAR-T Equecabtagene Autoleucel for MG
Details : CT103A (equecabtagene autoleucel) is a BCMA chimeric antigen receptor autologous T cell therapy, being investigated for the treatment of Generalized Myasthenia Gravis.
Product Name : CT103A
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 04, 2024
Lead Product(s) : Equecabtagene Autoleucel
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : APL-1401
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : APL-1401 is an oral drug got IND approval from NMPA for treatment of moderately-to-severely active ulcerative colitis, The IND application had previously been approved by the U.S. Food and Drug Administration.
Product Name : APL-1401
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 30, 2023
Lead Product(s) : APL-1401
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IASO-782
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IASO Bio Receives FDA Approval of IND Application for IASO-782 for Treatment of Autoimmune Disease
Details : IASO-782 Injection is a fully human monoclonal antibody targeting human CD19, with Fc mutations to enhance ADCC function for treatment of autoimmune disease.
Product Name : IASO-782
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
June 17, 2023
Lead Product(s) : IASO-782
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : T21
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Triastek Receives FDA IND Clearance for 3D Printed Medicine
Details : T21 is a novel potential treatment capable of colon-targeted drug delivery. With a unique 3D dosage form design, T21 can reach the targeted colon segment of the GI tract.
Product Name : T21
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2022
Lead Product(s) : T21
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable